Application now open for 2012 AACR-Kure It Grant for Kidney Cancer Research

NewsGuard 100/100 Score
The American Association for Cancer Research is pleased to announce a new partnership with Kure It and a call for nominations for the 2012 AACR-Kure It Grant for Kidney Cancer Research.

This two-year grant represents a joint effort to promote and support innovative kidney cancer research. The grant will support a translational research project designed to improve the survival and quality of life of patients with kidney cancer and, in turn, lead to individualized therapeutic options for the treatment or development of promising new kidney cancer therapies.

The grant recipient will receive $250,000 over the grant term (a two-year period) and complimentary registration to the AACR Annual Meeting 2013, to be held April 6-10 in Washington, D.C., where the recipient will be recognized.

Independent investigators are invited to submit proposals to develop and study new ideas and approaches that will have a direct application and relevance to patients with kidney cancer. The grant recipient will be selected by an expert scientific review committee of kidney cancer specialists assembled by the AACR.

The application deadline for the 2012 AACR-Kure It Grant for Kidney Cancer Research is at noon ET on Tuesday, Aug. 21, 2012.

The American Association for Cancer Research and Kure It are committed to sustaining the grant in a collaborative fashion to award research funding to the most promising kidney cancer research project.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer